{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:03Z","timestamp":1790270703453,"version":"4.1.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review summarizes recent insights and current understanding of the role of postactivated B cells in SLE and related pathogenic and potential therapeutic implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent finding<\/jats:title>\n                    <jats:p>B cells are considered key players in SLE and experience from various B-cell-targeted therapies underlines their clinical relevance. In the last years, new insights have been obtained on B-cell abnormalities within the complex pathophysiology of SLE. These insights involve a revised understanding of BCR signaling, that has been reported to be hyperresponsive in the past, but newer studies suggest a postactivation functiotype in terms of reduced BCR and TLR signaling. Despite comprehensive efforts to delineate B-cell abnormalities on assessing large-scale genomic, epigenomic and proteomic data, understanding functional impairments of cellular interactions and subcellular functions remains crucial. A recently identified enhanced protein tyrosine phosphatase (PTP) activity was found in relation to diminished BCR responses in SLE. This finding together with reduced cytokine production upon TLR9 activation appears to mark postactivated lupus B cells. Other studies identified increased PTP activity in line with a gain-of-function mutation of phosphatase PTPN22, one of the strongest SLE risk alleles. Improved understanding of these B cell abnormalities in SLE holds promise to gain further insights in mechanisms of autoimmunity and pave the way for selective therapies targeting key principles of chronic autoimmunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>SLE B cells (similar as previously described for lupus T cells) are characterized by a postactivation (exhausted) functiotype mandating consideration for innovative therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000576","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T18:33:32Z","timestamp":1544553212000},"page":"175-184","source":"Crossref","is-referenced-by-count":25,"title":["Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations"],"prefix":"10.1097","volume":"31","author":[{"given":"Eva","family":"Schrezenmeier","sequence":"first","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology"},{"name":"Department of Medicine\/Nephrology and Medical Intensive Care, Charit\u00e9 Universit\u00e4tsmedizin Berlin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Y.","family":"Wei\u00dfenberg","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology"},{"name":"Deutsches Rheumaforschungszentrum Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Luisa","family":"Stefanski","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology"},{"name":"University Clinic of Rheumatology, Immunology and Allergology, Inselspital Bern"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Szelinski","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology"},{"name":"Deutsches Rheumaforschungszentrum Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology"},{"name":"Deutsches Rheumaforschungszentrum Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia C.","family":"Lino","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology"},{"name":"Deutsches Rheumaforschungszentrum Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Rheumatology and Clinical Immunology"},{"name":"Deutsches Rheumaforschungszentrum Berlin (DRFZ), Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/imr.12660","article-title":"Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: a B-cell immunomics approach","volume":"284","author":"Tipton","year":"2018","journal-title":"Immunol Rev"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J Immunol"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s13075-014-0477-1","article-title":"Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation","volume":"16","author":"Sieber","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coi.2017.03.003","article-title":"Regulation of memory B and plasma cell differentiation","volume":"45","author":"Shinnakasu","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13075-018-1604-1","article-title":"Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus","volume":"20","author":"Julia","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1189\/jlb.0212095","article-title":"Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways","volume":"92","author":"Vaughn","year":"2012","journal-title":"J Leukoc Biol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/art.39559","article-title":"Enhanced tyrosine phosphatase activity underlies dysregulated B cell receptor signaling and promotes survival of human lupus B cells","volume":"68","author":"Fleischer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/eji.201747287","article-title":"Altered toll-like receptor responsiveness underlies a dominant heritable defect in B cell tolerance in autoimmune New Zealand Black mice","volume":"48","author":"Clark","year":"2018","journal-title":"Eur J Immunol"},{"key":"R9-20230829","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96795","article-title":"Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus","volume":"3","author":"Gies","year":"2018","journal-title":"JCI Insight"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fimmu.2018.00665","article-title":"Putting on the brakes: regulatory kinases and phosphatases maintaining B cell anergy","volume":"9","author":"Franks","year":"2018","journal-title":"Front Immunol"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3389\/fimmu.2017.01937","article-title":"Evidence for B cell exhaustion in chronic graft-versus-host disease","volume":"8","author":"Khoder","year":"2017","journal-title":"Front Immunol"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3389\/fimmu.2018.01088","article-title":"Aberrant T cell signaling and subsets in systemic lupus erythematosus","volume":"9","author":"Katsuyama","year":"2018","journal-title":"Front Immunol"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/emboj.2012.169","article-title":"Altered BCR signalling quality predisposes to autoimmune disease and a prediabetic state","volume":"31","author":"Konigsberger","year":"2012","journal-title":"EMBO J"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/ni.3175","article-title":"Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus","volume":"16","author":"Tipton","year":"2015","journal-title":"Nat Immunol"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"ra99","DOI":"10.1126\/scisignal.aaf2195","article-title":"Superresolution imaging of the cytoplasmic phosphatase PTPN22 links integrin-mediated T cell adhesion with autoimmunity","volume":"9","author":"Burn","year":"2016","journal-title":"Sci Signal"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.07.008","article-title":"Protein tyrosine phosphatase PTPN22 regulates LFA-1 dependent Th1 responses","volume":"94","author":"Sanchez-Blanco","year":"2018","journal-title":"J Autoimmun"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1080\/08916934.2017.1385774","article-title":"PTPN22 1858C > T polymorphism and susceptibility to systemic lupus erythematosus: a meta-analysis update","volume":"50","author":"de Lima","year":"2017","journal-title":"Autoimmunity"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/08916934.2015.1134514","article-title":"Meta-analysis reveals PTPN22\u200a1858C\/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian population","volume":"49","author":"Nabi","year":"2016","journal-title":"Autoimmunity"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clim.2016.10.015","article-title":"Increased frequency of the PTPN22W\u2217 variant in primary Sjogren's Syndrome: Association with low type I IFN scores","volume":"173","author":"Vlachogiannis","year":"2016","journal-title":"Clin Immunol"},{"key":"R21-20230829","doi-asserted-by":"crossref","DOI":"10.1177\/1179544117751434","article-title":"The protein tyrosine phosphatase nonreceptor 22 (PTPN22) R620W functional polymorphism in psoriasis","volume":"11","author":"Bin Huraib","year":"2018","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1172\/JCI45790","article-title":"The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans","volume":"121","author":"Menard","year":"2011","journal-title":"J Clin Invest"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"aaf7153","DOI":"10.1126\/sciimmunol.aaf7153","article-title":"PTPN22 inhibition resets defective human central B cell tolerance","volume":"1","author":"Schickel","year":"2016","journal-title":"Sci Immunol"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"26506","DOI":"10.1074\/jbc.M110.111104","article-title":"Autoimmune-associated PTPN22 R620W variation reduces phosphorylation of lymphoid phosphatase on an inhibitory tyrosine residue","volume":"285","author":"Fiorillo","year":"2010","journal-title":"J Biol Chem"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.3892\/mmr.2017.7527","article-title":"MicroRNA198 contributes to lupus nephritis progression by inhibition of phosphatase and tensin homology deleted on chromosome ten expression","volume":"16","author":"Cui","year":"2017","journal-title":"Mol Med Rep"},{"key":"R26-20230829","first-page":"7966","article-title":"Dysregulation of PTEN caused by the underexpression of microRNA130b is associated with the severity of lupus nephritis","volume":"17","author":"Wu","year":"2018","journal-title":"Mol Med Rep"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.1700138","article-title":"SHIP-1 Deficiency in AID(+) B Cells Leads to the Impaired Function of B10 Cells with Spontaneous Autoimmunity","volume":"199","author":"Chen","year":"2017","journal-title":"J Immunol"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1172\/JCI24895","article-title":"Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus","volume":"115","author":"Katsiari","year":"2005","journal-title":"J Clin Invest"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ni.3390","article-title":"Phosphatase PP2A is requisite for the function of regulatory T cells","volume":"17","author":"Apostolidis","year":"2016","journal-title":"Nat Immunol"},{"key":"R30-20230829","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23020395","article-title":"Proteinaceous regulators and inhibitors of protein tyrosine phosphatases","volume":"23","author":"Hendriks","year":"2018","journal-title":"Molecules"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1101\/gr.100289.109","article-title":"Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus","volume":"20","author":"Javierre","year":"2010","journal-title":"Genome Res"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaut.2013.04.003","article-title":"Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients","volume":"43","author":"Coit","year":"2013","journal-title":"J Autoimmun"},{"key":"R33-20230829","first-page":"285","article-title":"Murine models of lupus induced by hypomethylated T cells","volume":"102","author":"Richardson","year":"2004","journal-title":"Methods Mol Med"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2017-212379","article-title":"DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus","volume":"77","author":"Imgenberg-Kreuz","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"e1003678","DOI":"10.1371\/journal.pgen.1003678","article-title":"Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations","volume":"9","author":"Absher","year":"2013","journal-title":"PLoS Genet"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40422","article-title":"Twin DNA methylation profiling reveals flare-dependent interferon signature and B cell promoter hypermethylation in systemic lupus erythematosus","volume":"70","author":"Ulff-Moller","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1136\/annrheumdis-2015-208410","article-title":"IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus","volume":"75","author":"Zhao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/annrheumdis-2015-208659","article-title":"Genome-wide DNA methylation analysis in multiple tissues in primary Sjogren's syndrome reveals regulatory effects at interferon-induced genes","volume":"75","author":"Imgenberg-Kreuz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3389\/fimmu.2018.01637","article-title":"T follicular helper cells in autoimmune disorders","volume":"9","author":"Gensous","year":"2018","journal-title":"Front Immunol"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2003-06-2167","article-title":"Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura","volume":"103","author":"Kuwana","year":"2004","journal-title":"Blood"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1172\/JCI200319301","article-title":"Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions","volume":"112","author":"Grammer","year":"2003","journal-title":"J Clin Invest"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"839.e8","DOI":"10.1016\/j.jaci.2016.01.035","article-title":"T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity","volume":"138","author":"Szodoray","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13075-017-1258-4","article-title":"Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients","volume":"19","author":"Shi","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-016-0942-0","article-title":"PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus","volume":"18","author":"Luo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2018-eular.3451","article-title":"OP0253A phase III randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept or placebo on standard of care in patients with active class III or IV lupus nephritis","volume":"77","author":"Furie","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1002\/art.20519","article-title":"Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus","volume":"50","author":"Hutloff","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.40479","article-title":"Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keu369","article-title":"Belimumab after rituximab as maintenance therapy in lupus nephritis","volume":"53","author":"Kraaij","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jbspin.2016.01.008","article-title":"Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab","volume":"84","author":"Simonetta","year":"2017","journal-title":"Joint Bone Spine"},{"key":"R55-20230829","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sjogren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.it.2011.06.004","article-title":"BAFF and selection of autoreactive B cells","volume":"32","author":"Liu","year":"2011","journal-title":"Trends Immunol"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum BAFF levels are associated with rising antidouble-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"issue":"(Suppl 10)","key":"R59-20230829","first-page":"2018","article-title":"Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis [abstract]. In ACR","volume":"70","author":"Dall\u2019Era","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00296-016-3482-7","article-title":"Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"36","author":"Kunwar","year":"2016","journal-title":"Rheumatol Int"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1084\/jem.20161117","article-title":"TLR4 signals in B lymphocytes are transduced via the B cell antigen receptor and SYK","volume":"214","author":"Schweighoffer","year":"2017","journal-title":"J Exp Med"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"Mocsai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2018.03.062","article-title":"The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review","volume":"151","author":"Liang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.cell.2016.05.057","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study","volume":"70","author":"Merrill","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","article-title":"Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Isenberg","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R70-20230829","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R74-20230829","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase iii parent study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R75-20230829","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-017-1397-7","article-title":"Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity","volume":"19","author":"Ikeda","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R76-20230829","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/eji.201847492","article-title":"Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors","volume":"48","author":"Alexander","year":"2018","journal-title":"Eur J Immunol"},{"key":"R77-20230829","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R78-20230829","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich predisease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R79-20230829","doi-asserted-by":"crossref","first-page":"e8675","DOI":"10.1097\/MD.0000000000008675","article-title":"The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: a STROBE-compliant article","volume":"96","author":"Fang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R80-20230829","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/art.40181","article-title":"Plasmablasts with a mucosal phenotype contribute to plasmacytosis in systemic lupus erythematosus","volume":"69","author":"Mei","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201903000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:32:00Z","timestamp":1775302320000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201903000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000576","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}